Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.
about
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
P2860
Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Current results and future app ...... ent of non-Hodgkin's lymphoma.
@ast
Current results and future app ...... ent of non-Hodgkin's lymphoma.
@en
type
label
Current results and future app ...... ent of non-Hodgkin's lymphoma.
@ast
Current results and future app ...... ent of non-Hodgkin's lymphoma.
@en
prefLabel
Current results and future app ...... ent of non-Hodgkin's lymphoma.
@ast
Current results and future app ...... ent of non-Hodgkin's lymphoma.
@en
P2093
P2860
P1433
P1476
Current results and future app ...... ent of non-Hodgkin's lymphoma.
@en
P2093
Edgardo S Santos
Ernesto Ayala
Luis E Raez
Mohamed A Kharfan-Dabaja
P2860
P304
P356
10.1080/10428190600923140
P577
2006-12-01T00:00:00Z